1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Gout Therapeutics Market
2.3. Global Gout Therapeutics Market, By Drug Class, 2025 (US$ Million)
2.4. Global Gout Therapeutics Market, By Geography, 2025 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2025
3. Gout Therapeutics Market: Competitive Analysis
3.1. Market Positioning of Key Gout Therapeutics Market Vendors
3.2. Strategies Adopted by Gout Therapeutics Market Vendors
4. Gout Therapeutics Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Gout Therapeutics Market Value, 2024 - 2034, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. Porter's Five Force Model
4.5.1. Supplier Power
4.5.2. Buyer Power
4.5.3. Threat Of Substitutes
4.5.4. Threat Of New Entrants
4.5.5. Competitive Rivalry
4.6. PESTEL Analysis
4.6.1. Political Landscape
4.6.2. Economic Landscape
4.6.3. Social Landscape
4.6.4. Technology Landscape
4.6.5. Environmental Landscape
4.6.6. Legal Landscape
5. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2025 Versus 2034
5.3. Market Segmentation
5.3.1. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
5.3.2. Colchicine
5.3.3. Corticosteroids
5.3.4. Uric Acid Lowering Agents
6. North America Gout Therapeutics Market, 2024-2034, USD (Million)
6.1. Market Overview
6.2. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
6.3. Gout Therapeutics Market: By Region, 2024-2034, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
7. UK and European Union Gout Therapeutics Market, 2024-2034, USD (Million)
7.1. Market Overview
7.2. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
7.3. Gout Therapeutics Market: By Region, 2024-2034, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.5. France
7.3.1.5.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
8. Asia Pacific Gout Therapeutics Market, 2024-2034, USD (Million)
8.1. Market Overview
8.2. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
8.3. Gout Therapeutics Market: By Region, 2024-2034, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.3. India
8.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
9. Latin America Gout Therapeutics Market, 2024-2034, USD (Million)
9.1. Market Overview
9.2. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
9.3. Gout Therapeutics Market: By Region, 2024-2034, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10. Middle East and Africa Gout Therapeutics Market, 2024-2034, USD (Million)
10.1. Market Overview
10.2. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.3. Gout Therapeutics Market: By Region, 2024-2034, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Gout Therapeutics Market: By Drug Class, 2024-2034, USD (Million)
11. Company Profile
11.1. Ardea Biosciences, Inc. (Company Overview, Financial Performance, Product Portfolio, Strategic Initiatives)
11.2. AstraZeneca plc.
11.3. BioCryst Pharmaceuticals, Inc.
11.4. Cymabay Therapeutics, Inc.
11.5. GlaxoSmithKline plc.
11.6. Horizon Pharma Plc.
11.7. Novartis AG
11.8. Regeneron Pharmaceuticals, Inc.
11.9. Sanofi Aventis
11.10. Savient Pharmaceuticals, Inc.
11.11. Selecta Biosciences, Inc.
11.12. Takeda Pharmaceutical Company Ltd.
11.13. Teijin Pharma Ltd.
